Intravenous scopolamine hydrobromide — Competitive Intelligence Brief

Intravenous scopolamine hydrobromide (Intravenous scopolamine hydrobromide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic agent. Area: Anesthesia and Perioperative Medicine.

marketed Anticholinergic agent Muscarinic acetylcholine receptors Anesthesia and Perioperative Medicine Small molecule

Target snapshot

Intravenous scopolamine hydrobromide (Intravenous scopolamine hydrobromide) — University of Iowa. Scopolamine is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce secretions and motion-induced nausea.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intravenous scopolamine hydrobromide TARGET	Intravenous scopolamine hydrobromide	University of Iowa	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors
SCOPOLAMINE	SCOPOLAMINE		marketed	Anticholinergic [EPC]	Muscarinic acetylcholine receptors	1979-01-01
Enlon-Plus	Atropine Sulfate	Alcon Labs Inc	marketed	Antimuscarinic agent	Muscarinic acetylcholine receptors	1960-01-01
ACs	ACs	GlaxoSmithKline	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (non-selective or subtype-specific)
fenoterol/ipratropium bromide	fenoterol/ipratropium bromide	Novartis	marketed	Beta-2 agonist / Anticholinergic combination bronchodilator	Beta-2 adrenergic receptor (fenoterol); Muscarinic acetylcholine receptors (ipratropium bromide)
Neostigmine + Atropine	Neostigmine + Atropine	China Medical University Hospital	marketed	Cholinesterase inhibitor + Anticholinergic agent	Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (atropine)
Oxybutynin ER	Oxybutynin ER	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (M3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic agent class)

1. Repurposed Therapeutics, Inc. · 2 drugs in this class
2. University of Iowa · 2 drugs in this class
3. Alza Corporation, DE, USA · 2 drugs in this class
4. Janssen-Cilag Ltd.,Thailand · 1 drug in this class
5. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
6. Rutgers, The State University of New Jersey · 1 drug in this class
7. Stony Brook University · 1 drug in this class
8. Toronto Rehabilitation Institute · 1 drug in this class
9. US Department of Veterans Affairs · 1 drug in this class
10. University of California, Davis · 1 drug in this class